Literature DB >> 3476481

New morpholino anthracyclines, MX, MX2, and MY5.

H Umezawa, S Nakajima, H Kawai, N Komeshima, H Yoshimoto, T Urata, A Odagawa, N Otsuki, K Tatsuta, N Otake.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3476481     DOI: 10.7164/antibiotics.40.1058

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  6 in total

Review 1.  Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry.

Authors:  T Takeuchi
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.

Authors:  J Kuratsu; N Arita; K Kurisu; T Uozumi; T Hayakawa; Y Ushio
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

3.  Intrathecal chemotherapy with MX2 for treating glioma dissemination in vivo.

Authors:  S Mizumatsu; K Matsumoto; Y Ono; T Tamiya; T Furuta; T Ohmoto
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

4.  Laser flow cytometric studies on the intracellular accumulation of anthracyclines when combined with heat.

Authors:  Y Sakaguchi; Y Maehara; S Inutsuka; I Takahashi; M Yoshida; Y Emi; H Baba; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.

Authors:  A A Ebrahim el-Zayat; M A Izquierdo; G M Clark; D D Von Hoff
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

6.  Antitumor activity and pharmacokinetics of a morpholino-anthracycline derivative (KRN8602) against human breast carcinoma xenografts serially transplanted into nude mice.

Authors:  T Kubota; A Suto; K Josui; K Ishibiki; O Abe; Y Yamada; F Asanuma; E Kawamura; J Koh; E Shiina
Journal:  Jpn J Cancer Res       Date:  1990-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.